Additional file 7 of Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Authors :: Romito, Ilaria
Porru, Manuela
Braghini, Maria Rita
Pompili, Luca
Panera, Nadia
Crudele, Annalisa
Gnani, Daniela
De Stefanis, Cristiano
Scarsella, Marco
Pomella, Silvia
Levi Mortera, Stefano
de Billy, Emmanuel
Conti, Adrian Libenzio
Marzano, Valeria
Putignani, Lorenza
Vinciguerra, Manlio
Balsano, Clara
Pastore, Anna
Rota, Rossella
Tartaglia, Marco
Leonetti, Carlo
Alisi, Anna
Publication Year :: 2021
Publisher :: figshare, 2021.
Abstract: Additional file 7: Figure S2. Evaluation of the IC50 values of TAE226 and SOR on HCC cell viability after 2 and 5 days. Cell viability, measured by XTT assay, after 2 and 5 days from treatment with TAE226 or SOR, in HepG2 and Huh7 cells. Values are the mean OD �� SD of three independent experiments repeated at least in duplicate. Data were analysed by ANOVA. ***p

Full Text Access

Tools